Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 54

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 54
---
 COMMON SHAREHOLDERS  $(708,991) $(1,345,370) $(1,948,490) $(1,250,023)                 Other comprehensive income                Foreign currency translation gain  3,216   1,046,789   442,453   839,344                  COMPREHENSIVE LOSS $(705,775) $(298,581) $(1,506,037) $(410,679)                 Earnings per share - Basic and diluted  (0.395)  (0.749)  (1.085)  (0.704)Weighted average number of common stocks outstanding, Basic and Diluted #  1,796,597   1,796,766   1,796,597   1,776,766 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 1-for-10 reverse stock split effected on April 7, 2025, on a retroactive basis as described in Note 12.

 37Table of Contents

Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024.

  MRNA Scientific and Chemrex Corporation   Provision for genomic screening services  Trading of industrial chemicals  Provision for genomic screening services  Trading of industrial chemicals   Three months for period ended September 30, 2025  Three months for period ended September 30, 2024              REVENUE $4,768  $2,539,055  $2,563  $2,627,813                  COST OF REVENUE  (864)  (2,165,274)  (2,118)  (2,301,722)                 GROSS PROFIT  3,904   373,781   445   326,091                  OTHER INCOME                Dividend income   -   4,192   -   38,826 Interest income  18,552   2,226   19,224   15,798 Fair value gain on investments in equity securities  -   -   -   69,766 Gain on